Goede prijs.  online

details van de producten

Created with Pixso. Thuis Created with Pixso. Producten Created with Pixso.
Medicijnen tegen borst- en longkanker
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Merknaam: Boehringer Ingelheim
Modelnummer: 18 mg filmomhulde tabletten
MOQ: 1 st
Prijs: Please contact a specialist WhatsApp:55342706
Levertijd: Bespreekbaar
Betalingsvoorwaarden: Western Union, MoneyGram, T/T
Gedetailleerde informatie
Plaats van herkomst:
VS
Certificering:
FDA NDA 218764
Specificatie:
18mg*60 tabletten/doos
Aanwijzingen:
Idiopathische longfibrose, progressieve longfibrose
Doel:
PDE4B
Productnaam:
Nerandomilast
Adviseer:
Gelieve het advies van de arts op te volgen.
Opslag:
Bewaren bij 20°C tot 25°C, met schommelingen in de omgevingstemperatuur tussen 15°C en 30°C, uit de
Opslagtemperatuur:
20°C tot 25°C
Omgevingstemperatuurbereik:
15°C tot 30°C
Doseringsvorm:
Filmomhulde tablet
Tabletsterkte:
18 mg
Verpakkingsgrootte:
60 tabletten/doos
Doelenzym:
PDE4B
Verpakking Details:
Bespreekbaar
Levering vermogen:
Bespreekbaar
Markeren:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Productbeschrijving
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.